(Sharecast News) - Drugmaker GSK released two sets of trial data on Wednesday, covering its low-carbon asthma inhaler and a potential new treatment for multiple sclerosis.
GSK said its low-carbon version of Ventolin met all primary endpoints in a phase III study, showing non-inferiority in lung function compared to the current...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE